Direct accesses
Go to main menu
Go to main content
Menu
Search the site
Contact
Careers
You are viewing the website in English
en
fr
Search the site
Who
we are
Company
Leadership
Collaborations
Diseases
we target
Diseases we target
Leber Hereditary Optic Neuropathy (LHON)
Retinitis Pigmentosa (RP)
Geographic Atrophy in Dry-AMD
Our
technologies
Technologies we are applying
Gene Therapy
Mitochondrial Targeting Sequence (MTS)
Optogenetics
Clinical development Summary
Investors
Company Overview
Financial press releases
Investor Newsletters
Events & presentations
Stock information & Financial agenda
Governance
Documentation
Media
Conferences
Year
All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
News type
All
Regulatory
Clinical
Conferences
Corporate
Finance
General Meeting
Product candidates
Science & Technology
Other
Subject
All
General Assembly
Company and personnel
GS010 - LUMEVOQ
GS030
Technologies
Other
21 Sep 2021 - 23 Sep 2021
2nd Annual Gene Therapy for ophthalmic Disorders, digital event
15 Sep 2021 - 16 Sep 2021
5th Annual Cell & Gene Therapy World Asia, virtual
14 Sep 2021
Clinical Trials in Rare Diseases Conference 2021, Europe and USA, virtual conference
08 Sep 2021
Ophthalmology Futures Forums – Euro Retina Virtual Forum, September 8, 2021
02 Sep 2021 - 04 Sep 2021
2021 ISGEDR Meeting (International Society for Genetic Eye Diseases & Retinoblastoma)
01 September 2021
Clinical Data on GenSight Biologics’ LUMEVOQ® and GS030 Gene Therapies to be Presented at 2021 ISGEDR and Several Investor and Industry Meetings in September
20 Jul 2021
OIS European Innovation Showcase – Virtual
05 July 2021
GenSight Biologics to Host Key Opinion Leader Webcasts on the Topline Results from REFLECT Phase III Clinical Trial of LUMEVOQ®
29 Jun 2021 - 01 Jul 2021
Biotech Outsourcing Strategies (BOS) 2021, Virtual
24 Jun 2021 - 25 Jun 2021
UMDF Mitochondrial Medicine 2021 – virtual
View previous 9 articles
1
2
3
4
5
6
7
8
…
12
View next 9 articles
Go back to the page of the page